Table 1 Patient characteristicsa
Subpectoral (n = 29) | Prepectoral (n = 34) | p value* | |
|---|---|---|---|
No. of breasts | 35 | 35 | |
Age, years, mean ± SD (range) | 43.8286 ± 7.9428 | 47.2353 ± 10.6716 | 0.0693 |
≥ 0, N (%) | 2 (6.9%) | 0 (0%) | |
≥ 30, N (%) | 4 (13.8%) | 2 (5.9%) | |
≥ 40, N (%) | 21 (72.4%) | 20 (58.8%) | |
≥ 50, N (%) | 2 (6.9%) | 10 (29.4%) | |
≥ 60, N (%) | 0 (0%) | 2 (5.9%) | |
> 70, N (%) | 0 (0%) | 0 (0%) | |
BMI, kg/m2, mean ± SD (range) | 22.2214 ± 2.6532 (10.1751) | 22.0161 ± 2.3392 (9.8872) | 0.3670 |
Excised mass weight g, mean ± SD (range) | 318.8571 ± 122.2146 (292.1565) | 286.4706 ± 119.7632 (303.7712) | 0.0752 |
Silicone implant volume, cc, mean ± SD (range) | 346.7143 ± 169.202 (301.7834) | 284.4118 ± 157.1419 (310.9185) | 0.0588 |
Cancer staging, n (%) | 0.3494 | ||
0 | 9 (31.2%) | 7 (20.5%) | |
I | 15 (51.7%) | 17 (50%) | |
II | 3 (10.3%) | 9 (26.6%) | |
III | 2 (6.8%) | 1 (2.9%) | |
IV | 0 (0%) | 0 (0%) | |
Chemotherapy, n (%) | 0.1457 | ||
None | 22 (75.8%) | 12 (35.3%) | |
Neoadjuvant only | 0 (0%) | 0 (0%) | |
Neoadjuvant and adjuvant | 0 (0%) | 0 (0%) | |
Adjuvant only | 7 (24.2%) | 22 (64.7%) | |
Adjuvant hormone therapy | 18 (62.5%) | 22 (64.7%) | |
Radiotherapy, n (%) | 0.7598 | ||
None | 25 (86.2%) | 31 (91.20%) | |
Neoadjuvant | 0 (0%) | 0 (0%) | |
Adjuvant | 4 (13.8%) | 3 (8.8%) |